Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma
Open Access
- 18 October 2012
- journal article
- other
- Published by Wiley in British Journal of Haematology
- Vol. 160 (1) , 111-114
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding StudyClinical Cancer Research, 2010
- Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple MyelomaCancer Research, 2009
- Bortezomib, low‐dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myelomaBritish Journal of Haematology, 2009
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphomaLeukemia, 2007
- Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosisBlood, 2005
- Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancerJournal of Surgical Research, 2003
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood, 2003
- Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myelomaBlood, 2002
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984